BRPI0507050A - composto, composição farmacêutica, e, métodos para a fabricação de um medicamento para antagonizar o efeito da substáncia p em seu sìtio receptor, ou para o bloqueio dos receptores da neurocinina-1 e para a fabricação de um medicamento para o tratamento de um distúrbio fisiológico associado com um excesso de taquicininas em um mamìfero - Google Patents
composto, composição farmacêutica, e, métodos para a fabricação de um medicamento para antagonizar o efeito da substáncia p em seu sìtio receptor, ou para o bloqueio dos receptores da neurocinina-1 e para a fabricação de um medicamento para o tratamento de um distúrbio fisiológico associado com um excesso de taquicininas em um mamìferoInfo
- Publication number
- BRPI0507050A BRPI0507050A BRPI0507050-3A BRPI0507050A BRPI0507050A BR PI0507050 A BRPI0507050 A BR PI0507050A BR PI0507050 A BRPI0507050 A BR PI0507050A BR PI0507050 A BRPI0507050 A BR PI0507050A
- Authority
- BR
- Brazil
- Prior art keywords
- medicament
- manufacture
- tachykinins
- receptors
- excess
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 4
- 102000003141 Tachykinin Human genes 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 title abstract 3
- 108060008037 tachykinin Proteins 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 2
- 241000124008 Mammalia Species 0.000 title 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 title 1
- 230000000903 blocking effect Effects 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 abstract 2
- 102100024304 Protachykinin-1 Human genes 0.000 abstract 2
- 229940126601 medicinal product Drugs 0.000 abstract 2
- RCMLKQSZCSYLLS-UHFFFAOYSA-N 1-hydroxy-2,3-dihydroindole Chemical class C1=CC=C2N(O)CCC2=C1 RCMLKQSZCSYLLS-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
COMPOSTO, COMPOSIçãO FARMACêUTICA, E, MéTODOS PARA A FABRICAçãO DE UM MEDICAMENTO PARA ANTAGONIZAR O EFEITO DA SUBSTáNCIA P EM SEU SìTIO RECEPTOR, OU PARA O BLOQUEIO DOS RECEPTORES DA NEUROCININA-1 E PARA A FABRICAçãO DE UM MEDICAMENTO PARA O TRATAMENTO DE UM DISTúRBIO FISIOLóGICO ASSOCIADO COM UM EXCESSO DE TAQUICINAS EM UM MAMìFERO A presente invenção é direcionada a certos compostos de hidroisoindolina de Fórmula I, os quais são úteis como antagonistas de receptor da neurocinina-1 (NK-1), e inibidores da taquicinina e, em particular, da substância P. A invenção igualmente diz respeito a formulações farmacêuticas que compreendem estes compostos como ingredientes ativos e ao uso dos compostos e suas formulações no tratamento de certos distúrbios, incluindo a êmese, a incontinência urinária, a depressão e a ansiedade.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53991304P | 2004-01-27 | 2004-01-27 | |
| US56122704P | 2004-04-09 | 2004-04-09 | |
| PCT/US2005/002149 WO2005073191A1 (en) | 2004-01-27 | 2005-01-26 | Hydroisoindoline tachykinin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0507050A true BRPI0507050A (pt) | 2007-06-12 |
Family
ID=34830494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0507050-3A BRPI0507050A (pt) | 2004-01-27 | 2005-01-26 | composto, composição farmacêutica, e, métodos para a fabricação de um medicamento para antagonizar o efeito da substáncia p em seu sìtio receptor, ou para o bloqueio dos receptores da neurocinina-1 e para a fabricação de um medicamento para o tratamento de um distúrbio fisiológico associado com um excesso de taquicininas em um mamìfero |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US7217731B2 (pt) |
| EP (1) | EP1711465B1 (pt) |
| JP (1) | JP3987100B2 (pt) |
| KR (1) | KR20060127927A (pt) |
| AR (1) | AR047439A1 (pt) |
| AT (1) | ATE382034T1 (pt) |
| AU (1) | AU2005207934B2 (pt) |
| BR (1) | BRPI0507050A (pt) |
| CA (1) | CA2554550C (pt) |
| CO (1) | CO5700771A2 (pt) |
| CR (1) | CR8522A (pt) |
| CY (1) | CY1107167T1 (pt) |
| DE (1) | DE602005004011T2 (pt) |
| DK (1) | DK1711465T3 (pt) |
| EA (1) | EA010598B1 (pt) |
| EC (1) | ECSP066716A (pt) |
| ES (1) | ES2297687T3 (pt) |
| GE (1) | GEP20094691B (pt) |
| HR (1) | HRP20080100T3 (pt) |
| IL (1) | IL176879A0 (pt) |
| MA (1) | MA28359A1 (pt) |
| NI (1) | NI200600164A (pt) |
| NO (1) | NO339041B1 (pt) |
| NZ (1) | NZ548415A (pt) |
| PE (1) | PE20050687A1 (pt) |
| PL (1) | PL1711465T3 (pt) |
| PT (1) | PT1711465E (pt) |
| TW (1) | TWI341198B (pt) |
| UA (1) | UA84192C2 (pt) |
| WO (1) | WO2005073191A1 (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI341198B (en) * | 2004-01-27 | 2011-05-01 | Merck Sharp & Dohme | Hydroisoindoline tachykinin receptor antagonists |
| JP2008523147A (ja) * | 2004-12-14 | 2008-07-03 | メルク エンド カムパニー インコーポレーテッド | オクタヒドロピラノ［３，４−ｃ］ピロールタキキニン受容体拮抗薬 |
| AU2006261930B2 (en) * | 2005-06-27 | 2011-07-14 | Merck Sharp & Dohme Corp. | Hydroisoindoline tachykinin receptor antagonists |
| US20100036135A1 (en) | 2005-07-11 | 2010-02-11 | Merck & Co., Inc. | Process for Making Hydroisoindoline Tachykinin Receptor Antagonists |
| WO2007044296A2 (en) * | 2005-10-04 | 2007-04-19 | Merck & Co., Inc. | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence |
| WO2007075528A2 (en) * | 2005-12-22 | 2007-07-05 | Merck & Co., Inc. | Octahydropyrano[3,4-c]pyrrole tachykinin receptor antagonists |
| EP1978965A2 (en) * | 2006-01-24 | 2008-10-15 | Merck & Co., Inc. | Hexahydro-3h-pyrrolizin-3-ones useful as tachykinin receptor antagonists |
| JP2010502703A (ja) * | 2006-09-06 | 2010-01-28 | メルク エンド カムパニー インコーポレーテッド | 置換アミドの経口投与のための液体及び半固体の医薬製剤 |
| EP2089019A4 (en) * | 2006-11-02 | 2011-05-04 | Merck Sharp & Dohme | POLYMORPHIC OF A HYDROISOINDOLINE TACHYKININE RECEPTOR ANTAGONIST |
| AU2008233232A1 (en) * | 2007-03-29 | 2008-10-09 | Merck Sharp & Dohme Corp. | Combination therapy for the treatment-of lower urinary tract symptoms |
| AU2008236639B2 (en) * | 2007-04-10 | 2014-07-03 | Merck Sharp & Dohme Corp. | Hydroxymethyl ether hydroisoindoline tachykinin receptor antagonists |
| AU2011245499B2 (en) | 2010-04-30 | 2014-09-25 | Merck Sharp & Dohme Corp. | Novel beta 3 adrenergic receptor agonists |
| US8627816B2 (en) | 2011-02-28 | 2014-01-14 | Intelliject, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
| ES2672099T3 (es) | 2011-07-04 | 2018-06-12 | Irbm - Science Park S.P.A. | Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal |
| EP3013336A1 (en) * | 2013-06-24 | 2016-05-04 | Tigercat Pharma Inc. | Use of nk-1 receptor antagonist serlopitant in pruritus |
| US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| IL312486B2 (en) | 2017-04-10 | 2025-05-01 | Chase Therapeutics Corp | NK1 antagonist combination and method for treating synucleinopathies |
| KR20200026920A (ko) | 2017-06-30 | 2020-03-11 | 체이스 테라퓨틱스 코포레이션 | 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법 |
| CN111918647A (zh) | 2018-02-26 | 2020-11-10 | 圣拉斐尔医院有限公司 | 用于治疗眼痛的nk-1拮抗剂 |
| WO2021180885A1 (en) | 2020-03-11 | 2021-09-16 | Ospedale San Raffaele S.R.L. | Treatment of stem cell deficiency |
| MX2022011545A (es) | 2020-04-03 | 2022-11-09 | Nerre Therapeutics Ltd | Un antagonista de receptor de nk-1 para tratar una enfermedad que se selecciona de sepsis, choque septico, síndrome de dificultad respiratoria aguda (ards) 0 síndrome de disfunción orgánica múltiple (mcds). |
| IL298589A (en) | 2020-06-02 | 2023-01-01 | Nerre Therapeutics Ltd | Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650142A (en) * | 1995-09-27 | 1997-07-22 | Church & Dwight Co., Inc. | Bicarbonate-containing deodorant cosmetic stick compositions |
| EP0858444A4 (en) * | 1995-10-18 | 1999-12-01 | Merck & Co Inc | Cyclopentyl tachykinin receptor antagonists |
| WO2005032464A2 (en) | 2003-09-30 | 2005-04-14 | Merck & Co., Inc. | Phenyl pyrrolidine ether tachykinin receptor antagonists |
| TWI341198B (en) | 2004-01-27 | 2011-05-01 | Merck Sharp & Dohme | Hydroisoindoline tachykinin receptor antagonists |
-
2005
- 2005-01-20 TW TW094101721A patent/TWI341198B/zh not_active IP Right Cessation
- 2005-01-20 AR ARP050100203A patent/AR047439A1/es active IP Right Grant
- 2005-01-24 PE PE2005000090A patent/PE20050687A1/es not_active Application Discontinuation
- 2005-01-26 KR KR1020067015184A patent/KR20060127927A/ko not_active Ceased
- 2005-01-26 AU AU2005207934A patent/AU2005207934B2/en not_active Ceased
- 2005-01-26 DK DK05726323T patent/DK1711465T3/da active
- 2005-01-26 WO PCT/US2005/002149 patent/WO2005073191A1/en not_active Ceased
- 2005-01-26 EA EA200601378A patent/EA010598B1/ru not_active IP Right Cessation
- 2005-01-26 AT AT05726323T patent/ATE382034T1/de active
- 2005-01-26 PL PL05726323T patent/PL1711465T3/pl unknown
- 2005-01-26 JP JP2006551356A patent/JP3987100B2/ja not_active Expired - Fee Related
- 2005-01-26 US US11/043,213 patent/US7217731B2/en not_active Expired - Lifetime
- 2005-01-26 PT PT05726323T patent/PT1711465E/pt unknown
- 2005-01-26 GE GEAP20059594A patent/GEP20094691B/en unknown
- 2005-01-26 ES ES05726323T patent/ES2297687T3/es not_active Expired - Lifetime
- 2005-01-26 US US10/586,727 patent/US7645790B2/en active Active
- 2005-01-26 EP EP05726323A patent/EP1711465B1/en not_active Expired - Lifetime
- 2005-01-26 HR HR20080100T patent/HRP20080100T3/xx unknown
- 2005-01-26 BR BRPI0507050-3A patent/BRPI0507050A/pt not_active IP Right Cessation
- 2005-01-26 DE DE602005004011T patent/DE602005004011T2/de not_active Expired - Lifetime
- 2005-01-26 CA CA2554550A patent/CA2554550C/en not_active Expired - Fee Related
- 2005-01-26 UA UAA200609315A patent/UA84192C2/ru unknown
- 2005-01-26 NZ NZ548415A patent/NZ548415A/en not_active IP Right Cessation
-
2006
- 2006-07-16 IL IL176879A patent/IL176879A0/en unknown
- 2006-07-19 CR CR8522A patent/CR8522A/es not_active Application Discontinuation
- 2006-07-21 EC EC2006006716A patent/ECSP066716A/es unknown
- 2006-07-26 NI NI200600164A patent/NI200600164A/es unknown
- 2006-07-27 CO CO06073837A patent/CO5700771A2/es active IP Right Grant
- 2006-08-11 MA MA29265A patent/MA28359A1/fr unknown
- 2006-08-25 NO NO20063810A patent/NO339041B1/no not_active IP Right Cessation
-
2007
- 2007-03-06 US US11/714,352 patent/US7345083B2/en not_active Expired - Lifetime
-
2008
- 2008-01-31 CY CY20081100113T patent/CY1107167T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0507050A (pt) | composto, composição farmacêutica, e, métodos para a fabricação de um medicamento para antagonizar o efeito da substáncia p em seu sìtio receptor, ou para o bloqueio dos receptores da neurocinina-1 e para a fabricação de um medicamento para o tratamento de um distúrbio fisiológico associado com um excesso de taquicininas em um mamìfero | |
| BRPI0519262A2 (pt) | derivados de pirazol fundidos e mÉtodos de tratamento de distérbios metabàlicos-relacionados destes | |
| EA201391468A1 (ru) | 1,3-оксазины в качестве ингибиторов bace1 и/или bace2 | |
| BR0315115A (pt) | Compostos, composições farmacêuticas, método para tratar ou prevenir doenças ou distúrbios em que se requer um antagonista de receptores de orexina humana, processo para a fabricação de composições farmacêuticas, e, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| NO20092529L (no) | Substituerte 2,3-dihydroimidazo[1,2-c]kinazolinderivater som er anvendbare for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese | |
| EA201071040A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40 | |
| ATE445609T1 (de) | Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen | |
| BRPI0508461B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
| BR112022010891A2 (pt) | Combinação de um antagonista do receptor lpa1 de azetidina com agentes antifibróticos | |
| BR0315580A (pt) | Derivados de metileno uréia | |
| BR112014006763A2 (pt) | n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1 | |
| BRPI0508540A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0606675A2 (pt) | agonista receptor de neuropeptìdio-2, composições farmacêuticas que compreendem o mesmo, compostos, método para o tratamento terapêutico e/ou profilático de enfermidades e utilização dos compostos | |
| BR0104831A (pt) | Moduladores de receptor de glucocorticóide | |
| BRPI0412382A (pt) | composto , método para a verificação de novos compostos medicinais que se ligam a e modulam a atividade, por agonismo , agonismo parcial, ou antagonismo, do receptor de acetilcolina nicotìnico alfa7, método de tratamento ou profilaxia de uma doença ou condição humana, método para tratamento de jetlag, induzindo interrupção de fumar, vìcio em nicotina, abstinência, dor, e para colite ulcerativa, composição farmacêutica, e, método de tratamento ou prevenção de uma condição ou distúrbio que surge da disfunção de neurotransmissão do receptor de acetilcolina nicotìnico em um mamìfero, e, uso de um composto | |
| ATE459619T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| PE20060176A1 (es) | Antagonistas de cgrp seleccionados, procedimientos para su preparacion, y su empleo como medicamentos | |
| ATE455756T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| BR0314183A (pt) | Derivados de 1,4-diazabicicloalcano, quaisquer de seus enanciÈmeros ou qualquer mistura de seus enaciÈmeros, ou um seu sal de adição farmaceuticamente aceitável ou um seu n-óxido, composição farmacêutica, uso do dito composto, de qualquer um de seus enanciÈmeros ou de qualquer mistura de seus enanciÈmeros, ou de um seu sal de adição farmaceuticamente aceitável, e, método de tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou condição de um corpo animal vivo | |
| HK1203394A1 (en) | Ghrelin receptor agonists for the treatment of achlorhydria | |
| ATE473961T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| BRPI0409881A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| BRPI0512325A (pt) | composto, composição farmacêutica, e, método para a fabricação de um medicamento | |
| WO2007002457A3 (en) | Hydroisoindoline tachykinin receptor antagonists | |
| WO2007136570A3 (en) | 5,6-fused pyrrolidine compounds useful as tachykinin receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) Free format text: ALTERADO DE: MERCK AND CO., INC. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |